Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML
| Autor: | Ki-Sung Eom, Kim Yj, Sung-Moo Kim, Min Ws, Hyung-Ok Kim, Seok-Goo Cho, Sung Hyun Lee, Cho Bs, Chang-Ki Min, Chun-Choo Kim, Junguee Lee |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Transplantation Conditioning Adolescent medicine.medical_treatment Graft vs Host Disease Context (language use) Comorbidity Hematopoietic stem cell transplantation Donor Selection Young Adult Bone Marrow Internal medicine Granulocyte Colony-Stimulating Factor Confidence Intervals Living Donors medicine Humans Survival analysis Bone Marrow Transplantation Transplantation Donor selection business.industry Siblings Body Weight Organ dysfunction Hematopoietic Stem Cell Transplantation Hematology Middle Aged Survival Analysis Surgery Leukemia Myeloid Acute Treatment Outcome Quality of Life Female medicine.symptom Complication business Follow-Up Studies |
| Zdroj: | Bone Marrow Transplantation. 44:345-351 |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | We examined whether the use of G-CSF-primed unmanipulated bone marrow (pBM) permits successful transplantation in patients with adverse comorbid pretransplantation conditions. A total of 33 patients at variable risk of AML undergoing allogeneic SCT from an HLA-identical sibling participated. The patients suffered from a variety of treatment-related sequelae before SCT and many cases also featured the presence of major organ dysfunction. The median follow-up duration of patients who were among the overall survivors was 58 months (range, 11-125 months). The median number of CD34(+) cells infused was 3.5 x 10(6) per kg (range, 0.8-15.6 x 10(6) per kg). The median number of days for recovery of ANC and platelet count without transfusion was 13 (range, 6-22) and 18 (range, 11-29) days, respectively. Four patients (12%) died due to nonrelapse causes and only one patient developed the same course of infectious complication as before SCT. No particular finding in the context of CMV infection or other post transplant complication was observed. The estimated 10-year overall survival rate was 68%. Our results suggest that the use of pBM allows successful engraftment without increasing complications in patients with various comorbidities before transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|